Multi-omics approach to COVID-19: a domain-based literature review.

COVID-19 Conceptual domain Host signatures Omics Pathways Phenotypes SARS-CoV-2

Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
07 12 2021
Historique:
received: 25 08 2021
accepted: 23 11 2021
entrez: 8 12 2021
pubmed: 9 12 2021
medline: 15 12 2021
Statut: epublish

Résumé

Omics data, driven by rapid advances in laboratory techniques, have been generated very quickly during the COVID-19 pandemic. Our aim is to use omics data to highlight the involvement of specific pathways, as well as that of cell types and organs, in the pathophysiology of COVID-19, and to highlight their links with clinical phenotypes of SARS-CoV-2 infection. The analysis was based on the domain model, where for domain it is intended a conceptual repository, useful to summarize multiple biological pathways involved at different levels. The relevant domains considered in the analysis were: virus, pathways and phenotypes. An interdisciplinary expert working group was defined for each domain, to carry out an independent literature scoping review. The analysis revealed that dysregulated pathways of innate immune responses, (i.e., complement activation, inflammatory responses, neutrophil activation and degranulation, platelet degranulation) can affect COVID-19 progression and outcomes. These results are consistent with several clinical studies. Multi-omics approach may help to further investigate unknown aspects of the disease. However, the disease mechanisms are too complex to be explained by a single molecular signature and it is necessary to consider an integrated approach to identify hallmarks of severity.

Sections du résumé

BACKGROUND
Omics data, driven by rapid advances in laboratory techniques, have been generated very quickly during the COVID-19 pandemic. Our aim is to use omics data to highlight the involvement of specific pathways, as well as that of cell types and organs, in the pathophysiology of COVID-19, and to highlight their links with clinical phenotypes of SARS-CoV-2 infection.
METHODS
The analysis was based on the domain model, where for domain it is intended a conceptual repository, useful to summarize multiple biological pathways involved at different levels. The relevant domains considered in the analysis were: virus, pathways and phenotypes. An interdisciplinary expert working group was defined for each domain, to carry out an independent literature scoping review.
RESULTS
The analysis revealed that dysregulated pathways of innate immune responses, (i.e., complement activation, inflammatory responses, neutrophil activation and degranulation, platelet degranulation) can affect COVID-19 progression and outcomes. These results are consistent with several clinical studies.
CONCLUSIONS
Multi-omics approach may help to further investigate unknown aspects of the disease. However, the disease mechanisms are too complex to be explained by a single molecular signature and it is necessary to consider an integrated approach to identify hallmarks of severity.

Identifiants

pubmed: 34876157
doi: 10.1186/s12967-021-03168-8
pii: 10.1186/s12967-021-03168-8
pmc: PMC8649311
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

501

Subventions

Organisme : Ministero della Salute
ID : Ricerca Corrente program 1
Organisme : Ministero dell'Economia e delle Finanze
ID : CCR-2017-23669075
Organisme : H2020 European Research Council
ID : PANDORA-ID-NET

Informations de copyright

© 2021. The Author(s).

Références

Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
Int J Mol Sci. 2020 Jun 24;21(12):
pubmed: 32599910
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
Adv Virus Res. 2016;96:165-192
pubmed: 27712623
Clin Infect Dis. 2021 Sep 7;73(5):e1089-e1098
pubmed: 33220049
J Virol. 2018 Jan 30;92(4):
pubmed: 29167338
BioData Min. 2011 Apr 28;4:10
pubmed: 21527005
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Front Immunol. 2018 Mar 15;9:539
pubmed: 29599782
Prostaglandins Other Lipid Mediat. 2009 Sep;89(3-4):73-81
pubmed: 19383550
Cell Death Dis. 2021 Aug 12;12(8):788
pubmed: 34385425
Sci Data. 2020 May 5;7(1):136
pubmed: 32371892
Nat Rev Nephrol. 2021 Jan;17(1):46-64
pubmed: 33077917
Mini Rev Med Chem. 2009 Mar;9(3):368-78
pubmed: 19275729
J Lab Clin Med. 1995 Dec;126(6):530-40
pubmed: 7490512
Nat Med. 2021 Jan;27(1):28-33
pubmed: 33442016
Int J Evid Based Healthc. 2015 Sep;13(3):141-6
pubmed: 26134548
Immunity. 2019 Dec 17;51(6):1074-1087.e9
pubmed: 31784108
J Transl Med. 2020 Jun 10;18(1):233
pubmed: 32522207
Mol Syst Biol. 2021 Oct;17(10):e10387
pubmed: 34664389
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Int J Tryptophan Res. 2017 Mar 15;10:1178646917691938
pubmed: 28469468
NPJ Syst Biol Appl. 2018 Jun 2;4:21
pubmed: 29872544
BMC Infect Dis. 2017 May 16;17(1):349
pubmed: 28511640
Front Immunol. 2018 Jun 11;9:1298
pubmed: 29942307
Brief Bioinform. 2019 Mar 25;20(2):659-670
pubmed: 29688273
Nutr Metab Cardiovasc Dis. 2019 Oct;29(10):1040-1049
pubmed: 31377179
Sci Rep. 2019 Feb 28;9(1):3102
pubmed: 30816210

Auteurs

Chiara Montaldo (C)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Francesco Messina (F)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Isabella Abbate (I)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Manuela Antonioli (M)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Veronica Bordoni (V)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Alessandra Aiello (A)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Fabiola Ciccosanti (F)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Francesca Colavita (F)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Chiara Farroni (C)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Saeid Najafi Fard (S)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Emanuela Giombini (E)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Delia Goletti (D)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Giulia Matusali (G)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Gabriella Rozera (G)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Martina Rueca (M)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Alessandra Sacchi (A)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Mauro Piacentini (M)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.
Dept. Biology, University of Rome Tor Vergata, Via della Ricerca scientifica 1, Rome, Italy.

Chiara Agrati (C)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Gian Maria Fimia (GM)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.
Dept. Molecular Medicine, Sapienza University of Rome, 00185, Rome, Italy.

Maria Rosaria Capobianchi (MR)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy. maria.capobianchi@inmi.it.

Francesco Nicola Lauria (FN)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Giuseppe Ippolito (G)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Via Portuense, 292, 00149, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH